IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 82.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,978 shares of the company’s stock after selling 9,089 shares during the period. Wilmington Savings Fund Society FSB’s holdings in IDEXX Laboratories were worth $999,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. FSA Wealth Management LLC acquired a new position in IDEXX Laboratories during the third quarter valued at $25,000. Ridgewood Investments LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $27,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC grew its holdings in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares during the period. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in IDEXX Laboratories during the second quarter worth about $36,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.11% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Barclays dropped their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $539.63.

IDEXX Laboratories Stock Down 1.2 %

IDEXX Laboratories stock opened at $432.10 on Friday. The firm has a market capitalization of $35.38 billion, a P/E ratio of 41.67, a P/E/G ratio of 3.99 and a beta of 1.37. The stock’s fifty day simple moving average is $439.55 and its 200-day simple moving average is $471.57. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same quarter last year, the company earned $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.